ARE Stock Recent News
ARE LATEST HEADLINES
After covering the Winners of REIT Earnings Season last week, Part 2 of our Earnings Recap focuses on the worst-performing property sectors and common threads shared by these laggards. While there were no major "bombshells" this earnings season, there were pockets of relative weakness seen in the interest-rate-sensitive property sectors - net lease and office - along with goods-oriented sectors. Surging interest expense - not property-level fundamentals - was again the culprit behind much of this pain, underscoring the continued challenges facing more highly leveraged private real estate portfolios.
REIT stocks have become undervalued due to fear of office spreading to other unaffected sectors. There are 72 REITs trading below 15X AFFO, with many of them steadily growing earnings. High-quality REITs are trading at multiples that should be reserved for lower-quality companies, presenting an opportunity for investors.
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Alexandria Real Estate Equities (ARE) have what it takes?
Alexandria's (ARE) securing of renewal and lease extension with Takeda at Kendall Square in Cambridge highlights solid demand for its mega campus.
Alexandria Real Estate Equities: strong in biotech real estate. Realty Income: consistent monthly dividend payments.
Alexandria Real Estate Equities is a major owner of life sciences lab and office space. Agree Realty makes its living as a landlord to a laundry list of major retailers.
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Alexandria Real Estate Equities (ARE) have what it takes?
Even with the markets at all-time highs, there are still plenty of attractive values hiding in plain sight. Alexandria Real Estate's rent revenue and FFO per share both grew in Q4. The company's credit rating is firmly investment-grade, which provides it with a low cost of capital.
Alexandria Real Estate Equities is a blue-chip REIT focused on leasing to life science tenants in biotech and big pharma. The company has shown strong operational strength with near-perfect rent collections, high leasing volumes, and long-term leases with high rent spreads. ARE's development pipeline is expected to contribute to significant growth in NOI, and its long-duration balance sheet mitigates the impact of rising interest rates.